UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 142

Sortiert nach

Monoclonal Antibody Monitoring: Clinically Relevant Aspects, A Systematic Critical Review

Therapeutic drug monitoring, 2020-02, Vol.42 (1), p.45

2020

Volltextzugriff (PDF)

Autologous Mesenchymal Stromal Cells and Kidney Transplantation: A Pilot Study of Safety and Clinical Feasibility

Clinical journal of the American Society of Nephrology, 2011-02, Vol.6 (2), p.412-422

2011

Volltextzugriff (PDF)

Third‐party bone marrow–derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial

American journal of transplantation, 2021-08, Vol.21 (8), p.2795-2809

2021

Volltextzugriff (PDF)

Direct targeting of cancer cells with antibodies: What can we learn from the successes and failure of unconjugated antibodies for lymphoid neoplasias?

Journal of autoimmunity, 2017-12, Vol.85, p.6-19

Golay, Josée

2017

Volltextzugriff (PDF)

phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

Annals of hematology, 2010-02, Vol.89 (2), p.185-190

2010

Volltextzugriff (PDF)

Tolerance to Bone Marrow Transplantation: Do Mesenchymal Stromal Cells Still Have a Future for Acute or Chronic GvHD?

Frontiers in immunology, 2020-12, Vol.11, p.609063-609063

2020

Volltextzugriff (PDF)

Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays

Archives of biochemistry and biophysics, 2012-10, Vol.526 (2), p.146-153

2012

Volltextzugriff (PDF)

Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies

Frontiers in immunology, 2022-06, Vol.13, p.929895-929895

2022

Volltextzugriff (PDF)

Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate

Cytotherapy (Oxford, England), 2011-08, Vol.13 (7), p.786-801

2011

Volltextzugriff (PDF)

Cord blood–derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19+ tumors

Cytotherapy (Oxford, England), 2018-08, Vol.20 (8), p.1077-1088

2018

Volltextzugriff (PDF)

The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies

Haematologica (Roma), 2017-10, Vol.102 (10), p.e400

2017

Volltextzugriff (PDF)

Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies

Blood, 2017-05, Vol.129 (19), p.2636-2644

2017

Volltextzugriff (PDF)

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab

Blood, 2013-11, Vol.122 (20), p.3482-3491

2013

Volltextzugriff (PDF)

Key Features Defining the Disposition of Bispecific Antibodies and Their Efficacy In Vivo

Therapeutic drug monitoring, 2020-02, Vol.42 (1), p.57

2020

Volltextzugriff (PDF)

Human neutrophils express low levels of FcγRIIIA, which plays a role in PMN activation

Blood, 2019-03, Vol.133 (13), p.1395-1405

2019

Volltextzugriff (PDF)

Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity

Blood, 2011-09, Vol.118 (12), p.3301-3310

2011

Volltextzugriff (PDF)

Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy

The Journal of immunology (1950), 2013-01, Vol.190 (1), p.231-239

2013

Volltextzugriff (PDF)

Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab

The Journal of immunology (1950), 2011-03, Vol.186 (6), p.3762-3769

2011

Volltextzugriff (PDF)

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs

Antibodies (Basel), 2020-10, Vol.9 (4), p.58

2020

Volltextzugriff (PDF)

M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro

The Journal of immunology (1950), 2009-04, Vol.182 (7), p.4415-4422

2009

Volltextzugriff (PDF)

The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia

PloS one, 2013-03, Vol.8 (3), p.e58424-e58424

2013

Volltextzugriff (PDF)

Comment on "Reduced T-dependent humoral immunity in CD20-deficient mice"

The Journal of immunology (1950), 2013-12, Vol.191 (12), p.5783-5783

Golay, Josée

2013

Volltextzugriff (PDF)

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

Haematologica (Roma), 2015-01, Vol.100 (1), p.77

2015

Volltextzugriff (PDF)

The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells

Blood, 2003-08, Vol.102 (3), p.956-963

2003

Volltextzugriff (PDF)

Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo

The Journal of immunology (1950), 2003-08, Vol.171 (3), p.1581-1587

2003

Volltextzugriff (PDF)

1 – 25 von 142

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(136)
Mit Volltextzugriff
(124)

Publikationsform

Artikel
(142)

Sprache

Englisch
(142)
Japanisch
(23)

Erscheinungsjahr

n.n

Thema

Science & Technology
(99)
Life Sciences & Biomedicine
(97)
Humans
(86)
Hematology
(55)
Biological And Medical Sciences
(33)
Immunology
(26)
Medical Sciences
(24)
Animals
(22)
Rituximab
(22)
Tumor Cells, Cultured
(18)
Antibodies, Monoclonal - Pharmacology
(17)
Medicine, Research & Experimental
(17)
Research & Experimental Medicine
(17)
Cell Line, Tumor
(15)
Hematologic And Hematopoietic Diseases
(15)
Antibodies, Monoclonal, Murine-Derived
(14)
Mice
(14)
Adult
(12)
Male
(12)
Antigens, Cd20 - Immunology
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Monoclonal Antibody Monitoring: Clinically Relevant Aspects, A Systematic Critical Review

Autologous Mesenchymal Stromal Cells and Kidney Transplantation: A Pilot Study of Safety and Clinical Feasibility

Third‐party bone marrow–derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial

Direct targeting of cancer cells with antibodies: What can we learn from the successes and failure of unconjugated antibodies for lymphoid neoplasias?

phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

Tolerance to Bone Marrow Transplantation: Do Mesenchymal Stromal Cells Still Have a Future for Acute or Chronic GvHD?

Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays

Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies

Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate

Cord blood–derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19+ tumors

The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies

Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab

Key Features Defining the Disposition of Bispecific Antibodies and Their Efficacy In Vivo

Human neutrophils express low levels of FcγRIIIA, which plays a role in PMN activation

Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity

Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy

Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs

M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro

The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia

Comment on "Reduced T-dependent humoral immunity in CD20-deficient mice"

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells

Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo

Suchergebnisse filtern